Quick Answer
Regencell Bioscience Holdings Ltd reported Cash and Equivalents of $6.42 million for fiscal year 2022.
Regencell Bioscience Holdings Ltd Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $6.42M | +10700.7% |
| 2021 | $59.4K | -84.6% |
| 2020 | $387.0K | +59.0% |
| 2019 | $243.3K | +58.7% |
| 2018 | $153.3K | — |
- Regencell Bioscience Holdings Ltd showed an increase of +10700.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2022 period, Regencell Bioscience Holdings Ltd’s cash and equivalents has grown by 4085.8% (from $153.3 thousand to $6.42 million).
- The most recent figure is from Regencell Bioscience Holdings Ltd’s fiscal year 2022 report (Form 20-F), filed with the SEC on October 31, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: